Neulasta® (pegfilgrastim)

DRUG3 trials

Sponsors

Amgen, EVIVE Biotechnology, Buddhist Tzu Chi General Hospital

Conditions

Breast CancerNeutropeniaNon-Small Cell Lung CancerTraumatic Optic Neuropathy

Early Phase 1

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Buddhist Tzu Chi General HospitalTraumatic Optic Neuropathy

Start: 2020-07-24End: 2024-12-31Target: 20Updated: 2023-12-13

Phase 2

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

CompletedNCT01648322

EVIVE BiotechnologyBreast Cancer, Neutropenia

Start: 2012-06-30End: 2014-12-31Updated: 2018-10-03

Phase 4

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

CompletedNCT00115206

AmgenNon-Small Cell Lung Cancer

Start: 2002-07-31End: 2004-07-31Updated: 2009-04-06

Related Papers

Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.

2024-01-094 citations